STAT January 8, 2024
Daniel Weiner

Few medications have captured the national attention like Wegovy — and for good reason. In a country with a well-documented obesity epidemic, Wegovy and other members of a new type of weight-loss drug are highly effective: In clinical trials, people on Wegovy typically lose 15% of body weight, and a similar medication, retatrutide, has shown up to 24% weight loss. There is now evidence that they confer benefit beyond weight loss, including a recent large clinical trial demonstrating protection against cardiovascular disease.

Yet Medicare does not cover Wegovy, or any other weight loss prescription. State Medicaid programs may decide to cover weight loss drugs, and only a fairly small number currently offer Wegovy.

It’s easy to assume these restrictions emerged...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech, Provider
109 hospitals receiving new Medicare-backed residency slots
Senators urge Congress to avert Medicare physician pay cut
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes

Share This Article